title: Invasive pneumococcal disease in patients with haematological malignancies before routine use of conjugate vaccines in Finland.
abstract: The baseline national invasive pneumococcal disease (IPD) incidence rate, serotype distribution and serotype coverage of pneumococcal vaccines were evaluated in patients with Hodgkin's and non-Hodgkin's lymphomas, myeloma and leukaemia within 1 year after haematological diagnosis during 1995-2002, before introduction of pneumococcal conjugate vaccines. Pneumococcal serotype distribution among these patients was different from serotypes causing IPD in the general population. The serotype coverages of PCV13 and PPSV23 were 57% and 64%, respectively, lower than in the general population. This reflects a higher predisposition to IPD in vaccinated patients with haematological malignancies and possibly less benefit of herd immunity gained with the wide use of pneumococcal conjugate vaccines in the general population. This data will be useful as a baseline for determining the future role of adult PCV vaccination in these patient groups.
authors.affiliation: a Cancer Center, Department of Hematology , Helsinki University Hospital , Helsinki , Finland ;
authors.forename: Vesa
authors.initials: V
authors.lastname: Lindström
authors.affiliation: b Department of Clinical Microbiology , Fimlab Laboratories , Tampere , Finland ;
authors.forename: Janne
authors.initials: J
authors.lastname: Aittoniemi
authors.affiliation: c Epidemiologic Surveillance and Control Unit, Department of Infectious Disease Surveillance and Control , National Institute for Health and Welfare (THL) , Helsinki , Finland ;
authors.forename: Outi
authors.initials: O
authors.lastname: Lyytikäinen
authors.affiliation: d Porvoo Hospital , Porvoo , Finland ;
authors.forename: Peter
authors.initials: P
authors.lastname: Klemets
authors.affiliation: c Epidemiologic Surveillance and Control Unit, Department of Infectious Disease Surveillance and Control , National Institute for Health and Welfare (THL) , Helsinki , Finland ;
authors.forename: Jukka
authors.initials: J
authors.lastname: Ollgren
authors.affiliation: e Department of Medicine , Kuopio University Hospital , Kuopio , Finland ;
authors.forename: Raija
authors.initials: R
authors.lastname: Silvennoinen
authors.affiliation: c Epidemiologic Surveillance and Control Unit, Department of Infectious Disease Surveillance and Control , National Institute for Health and Welfare (THL) , Helsinki , Finland ;|f School of Health Sciences , University of Tampere , Finland ;
authors.forename: J Pekka
authors.initials: JP
authors.lastname: Nuorti
authors.affiliation: g Department of Internal Medicine , Tampere University Hospital , Tampere , Finland.
authors.forename: Marjatta
authors.initials: M
authors.lastname: Sinisalo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D005387:Finland / Q000453:epidemiology; D019337:Hematologic Neoplasms / Q000150:complications* / Q000453:epidemiology*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000150:complications / Q000453:epidemiology / Q000382:microbiology; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate; D055815:Young Adult
chemical_list: D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate
keywords: Invasive pneumococcal disease; haematological malignancies; pneumococcal vaccines; serotype coverage; serotype distribution